



2024 CIBMTR Report of Survival Statistics for Blood and Marrow Transplants

September 12, 2025

Contents

| | |
|---------------------|----|
| Abbreviations | 4 |
| Introduction | 5 |
| Results | 6 |
| References | 80 |

Tables

| | |
|---|----|
| Table 1 Patients aged \leq 18, autoHCT for NHL during July 2010-June 2022 | 7 |
| Table 2 Patients aged >18 , autoHCT for NHL during July 2010-June 2022 | 8 |
| Table 3 Patients aged \leq 18, autoHCT for HL during July 2010-June 2022, by remission status | 10 |
| Table 4 Patients aged >18 , autoHCT for HL during July 2010-June 2022, by remission status | 11 |
| Table 5 Patients aged \leq 18, autoHCT for AML during July 2010-June 2022, by remission status | 13 |
| Table 6 Patients aged >18 , autoHCT for AML during July 2010-June 2022, by remission status | 14 |
| Table 7 Patients aged \leq 18, autoHCT ALL during July 2010-June 2022, by remission status | 15 |
| Table 8 Patients aged >18 , autoHCT for ALL during July 2010-June 2022, by remission status | 16 |
| Table 9 Patients of all ages, autoHCT for MM during July 2010-June 2022 | 17 |
| Table 10 Patients of all ages, autoHCT for neuroblastoma during July 2010-June 2022 | 18 |
| Table 11 Patients of all ages, autoHCT for testicular cancer during July 2010-June 2022 | 19 |
| Table 12 Patients aged \leq 18, autoHCT for CNS (except CNS lymphoma and neuroblastoma) during July 2010-June 2022 | 20 |
| Table 13 Patients aged >18 , autoHCT for CNS tumors (except CNS lymphoma and neuroblastoma) during July 2010-June 2022 | 21 |
| Table 14 Patients of all ages, HLA-identical sibling HCT for CML during July 2010-June 2022, by disease phase | 22 |
| Table 15 Patients of all ages, HCT other than HLA-identical sibling for CML during July 2010-June 2022, by disease phase | 24 |
| Table 16 Patients aged \leq 18, HLA-identical sibling HCT for AML during July 2010 and June 2022, by disease status | 27 |
| Table 17 Patients aged >18 , HLA-identical sibling HCT for AML during July 2010-June 2022, by remission status | 29 |
| Table 18 Patients aged \leq 18, from donors other than HLA-identical sibling for AML during July 2010-June 2022, by remission status | 31 |
| Table 19 Patients aged >18 , HCT from donors other than HLA-identical sibling for AML during July 2010-June 2022, by remission status | 34 |
| Table 20 Patients aged \leq 18, HLA-identical sibling HCT for ALL during July 2010-June 2022, by remission status | 37 |

| | |
|--|--|
| Table 21 Patients aged >18, HLA-identical sibling HCT for ALL during July 2010-June 2022, by remission status..... | 39 |
| Table 22 Patients aged ≤ 18, HCT from donors other than HLA-identical siblings for ALL during July 2010-June 2022, by remission status..... | 41 |
| Table 23 Patients aged >18, HCT from donors other than HLA-identical siblings for ALL during July 2010-June 2022, by remission status..... | 43 |
| Table 24 Patients of all ages, HLA-identical sibling HCTs for MDS during July 2010-June 2022, by disease stage..... | 46 |
| Table 25 Patients of all ages, HCT from donors other than HLA-identical siblings for MDS during July 2010-June 2022, by disease stage | 48 |
| Table 26 Patients of all ages, HLA-identical sibling HCT for NHL during July 2010-June 2022, by disease subtype | 50 |
| Table 27 Characteristics of patients receiving transplants from donors other than HLA-identical siblings for non-Hodgkin lymphoma during July 2010-June 2022, by disease stage | 54 |
| Table 28 Characteristics of patients receiving allogeneic transplants for Hodgkin lymphoma during July 2010-June 2022, by donor type | 58 |
| Table 29 Characteristics of patients receiving HLA-identical sibling transplants for multiple myeloma during July 2010-June 2022, by time from DX to HCT | 61 Error! Bookmark not defined. |
| Table 30 Characteristics of patients receiving transplants from donors other than HLA-identical siblings for multiple myeloma during July 2010-June 2022, by time from DX to HCT | 63 |
| Table 31 Characteristics of patients ≤ 18 years of age receiving allogeneic transplants for severe aplastic anemia during July 2010-June 2022, by donor type..... | 65 |
| Table 32 Characteristics of patients > 18 years of age receiving allogeneic transplants for severe aplastic anemia during July 2010-June 2022, by donor type..... | 68 |
| Table 33 Characteristics of patients receiving allogeneic transplants for Fanconi anemia during July 2010-June 2022, by donor type | 71 |
| Table 34 Characteristics of patients receiving allogeneic transplants for thalassemia between July 2010-June 2022, by donor type | 73 |
| Table 35 Characteristics of patients receiving allogeneic transplants for SCID during July 2010-June 2022, by donor type..... | 75 |
| Table 36 Characteristics of patients receiving allogeneic transplants for inherited disorders during July 2010-June 2022, by donor type | 77 |

Abbreviations

| Abbreviation | Expansion |
|--------------|---|
| ALL | acute lymphoblastic leukemia |
| alloHCT | allogeneic hematopoietic cell transplantation |
| AML | acute myeloid leukemia |
| autoHCT | autologous hematopoietic cell transplantation |
| BEAM | BCNU [carmustine], etoposide, Ara-C [cytarabine], and melphalan |
| Bu | busulfan |
| Carb | carboplatin |
| CBV | cyclophosphamide, BCNU [carmustine], and VP-16 [etoposide] |
| CML | chronic myeloid leukemia |
| CNI | calcineurin inhibitor |
| CNS | central nervous system |
| CR | complete remission |
| CR ≥ 2 | second or greater complete remission |
| CR1 | first complete remission |
| Cy | cyclophosphamide |
| Dx | diagnosis |
| Etop | etoposide |
| FA | Fanconi anemia |
| FCR | fludarabine, cyclophosphamide and rituximab |
| Flu | fludarabine |
| GVHD | graft-versus-host disease |
| HCT | hematopoietic cell transplantation |
| HL | Hodgkin lymphoma |
| HLA | human leukocyte antigen |
| MDS | myelodysplastic syndrome |
| Mel | melphalan |
| MM | multiple myeloma |
| MMF | mycophenolate mofetil |
| MTX | methotrexate |
| NE | not evaluable |
| NHL | non-Hodgkin lymphoma |
| NMA | non-myeloablative |
| PR | partial remission |
| PTCy | post-transplant cyclophosphamide |
| RIC | reduced-intensity conditioning |
| SAA | severe aplastic anemia |
| SCID | severe combined immunodeficiency |
| TBI | total body irradiation |
| TLI | total lymphoid irradiation |
| TT | thiotepa |
| VP | etoposide |

Introduction

The following tables describe the use and outcome of autologous and allogeneic blood and bone marrow transplants in the more than 350 centers participating in CIBMTR® (Center for International Blood and Marrow Transplant Research®). Prior to 2007, we estimate CIBMTR captured 90% of all unrelated donor transplants performed in the US, 60-90% of related donor allogeneic transplants, and 65-75% of autologous transplants. After 2007, CIBMTR collects data on all allogeneic transplants performed in the US and 80% of autologous transplants.

Table 1-13 (autologous) and Tables 14-36 (allogeneic) show patient characteristics and probabilities of survival ($\pm 95\%$ CIs) post-transplant at 100 days, and at 1, 3 and 5 years. Categorical variables are represented by N (%), continuous variables by median (range). Probabilities were calculated using the Kaplan-Meier estimator. Some groups lack sufficient data for calculation of probabilities beyond 2-3 years. These are indicated by footnotes which give the time of the last censored observation. Outcomes were stratified on disease and disease state pre-transplant. However, it should be remembered that these groups are still heterogeneous with regard to age, prior treatment, chemotherapy-sensitivity and other important prognostic factors. Extrapolating to individual patients or centers may not be appropriate.

The enclosed raw data represents a preliminary review of information registered to CIBMTR. The analysis has not been reviewed or approved by the Advisory or Scientific Committee of CIBMTR.

PLEASE NOTE: The enclosed data are for your own information and may be used in oral, but not written presentations. Unauthorized reproduction is prohibited.

Please contact CIBMTR for information on obtaining written permission to reproduce the enclosed data.

Data source

the Medical College of Wisconsin and NMDP. CIBMTR collaborates with scientists around the globe to study cellular therapies and cure life-threatening diseases, many of which are rare.

More than 310 medical centers worldwide submit clinical data to CIBMTR about hematopoietic cell transplantation and other cellular therapies, such as chimeric antigen receptor T cells (CAR-Ts). These therapies treat malignant and non-malignant hematologic conditions and some other disorders. By analyzing these data, CIBMTR identifies the best treatments to help people live longer and enjoy better quality of life.

CIBMTR also collects and analyzes participant-reported outcomes and quality of life data.

CIBMTR maintains one of the world's largest observational databases of clinical information on HCT and other cellular therapies. Data are collected, stored, and shared under terms of the *Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries* and its accompanying consent forms.¹⁻⁵ At the time of treatment, patients consent for their data to be entered into the Research Database and used to support a broad research agenda. Currently, CIBMTR's Research Database includes long-term clinical data from more than 700,000 patients.

The database includes:

- Almost 100% of allogeneic transplants in the US
- More than 85% of autologous transplants in the US
- About 27,500 patients who received other cellular therapies

CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database, awarded by the Health Resources and Services Administration of the US Department of Health and Human Services. As the contract holder, CIBMTR is charged with collecting data on all allogeneic (related and unrelated) hematopoietic cell transplants performed in the US. All US transplant centers are required to report data to CIBMTR; participation of non-US centers is voluntary.

CIBMTR also maintains a biorepository with tissue samples.⁵ CIBMTR's unique staff of physicians, biostatisticians, research coordinators, data management staff and IT teams conduct both observational research and clinical trials.

Transplant data

CIBMTR collects transplant data on 2 levels: Transplant Essential Data (TED) and Comprehensive Report Form (CRF). CIBMTR collects TED data on all patients. TED data are an internationally accepted standard data set that includes hundreds of details about patients' demographics, disease, treatment, response, side effects, and long-term outcomes. Using a regularly reviewed, weighted algorithm, CIBMTR selects a subset of patients for more detailed CRF data collection.

Approximately 75% of CIBMTR centers provide CRF data; this accounts for more than 25% of cases submitted to CIBMTR annually.

TED and CRF data are collected pre-transplant, 100 days post-transplant, 6 months post-transplant, annually until year 6 post-transplant, and biannually thereafter until death or lost to follow-up.

Data quality

CIBMTR subjects data to a series of automated and manual quality checks. CIBMTR data operations teams work directly with centers to maintain both consistency and quality of data collected. In addition, CIBMTR performs on-site source data audits, and each member center is audited within a 4-year cycle. These validations and verifications produce high-quality data. If a center fails to meet data quality standards, its data are removed (embargoed) from research studies.

Ethics

CIBMTR protects the privacy and human rights of participants.⁶ CIBMTR obeys international laws and ethical guidelines, including the United States Health Insurance Portability and Accountability Act (HIPAA) and the European Union's General Data Protection Regulation (GDPR). The NMDP Institutional Review Board, which is fully accredited by the Association for the Accreditation of Human Research Protection Programs, reviews CIBMTR's research. Patients and/or guardian(s) give informed consent for research.

Results

Note: The enclosed data are confidential and represent a preliminary review of information submitted to the CIBMTR. The analysis has not been reviewed or approved by the Statistical or Scientific Committees of the CIBMTR. The data may not be published without prior approval of the CIBMTR.